# ExpreS2ion Biotech Holding

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/expres2ionbiotechholding).

## Overview

ExpreS2ion Biotech Holding AB is a Swedish biotechnology holding company built around the ExpreS2 recombinant protein expression platform. Through its operating subsidiary ExpreS2ion Biotechnologies ApS, it develops protein-based vaccine and oncology assets, provides contract research services, and holds interests in collaborative vaccine technology ventures such as AdaptVac.

## Products & services

• ExpreS2 recombinant protein expression platform
• ES2B-C001 oncology vaccine program
• Contract protein expression and process development
• Research-grade and preclinical protein supply
• GlycoX-S2 glycosylation technologies
• Platform licensing and technology transfer
• Collaborative vaccine R&D programs

- **Proprietary therapeutic programs** (35%) — Internally developed vaccine and oncology assets advanced through discovery, preclinical and clinical stages.
- **Contract research services** (30%) — Fee-based protein expression, process development and material supply for external partners.
- **Platform licensing and technology transfer** (15%) — Licensing of the ExpreS2 platform and transfer of know-how to partners and CDMOs.
- **Collaborative infectious disease programs** (20%) — Publicly funded and partnered vaccine research in malaria, influenza, Nipah and related areas.

- ExpreS2 recombinant protein expression platform
- ES2B-C001 oncology vaccine program
- Contract protein expression and process development
- Research-grade and preclinical protein supply
- GlycoX-S2 glycosylation technologies
- Platform licensing and technology transfer
- Collaborative vaccine R&D programs

## Customers

The company sells primarily to biotechnology and pharmaceutical companies, academic groups, and research consortia that need difficult-to-express proteins or vaccine antigens. Its proprietary pipeline is aimed at clinical and translational development partners in oncology, while its platform services are used by organizations that want expression, optimization, or material supply for discovery and preclinical work.

- **Biotechnology and pharmaceutical companies** (primary) — Buy protein expression, process development and research-grade material for difficult constructs and preclinical programs
- **Academic and translational research groups** (secondary) — Use the ExpreS2 platform for discovery-stage expression work and antigen production
- **Public research consortia and grant-funded programs** (secondary) — Collaborate on malaria, influenza and Nipah vaccine research using the platform
- **Clinical and development partners** (primary) — Engage around ES2B-C001 and other assets as programs move toward clinical evaluation
- **CDMOs and technology recipients** (emerging) — Receive transferred processes and platform know-how for downstream manufacturing

- Biotech and pharma companies needing complex protein expression
- Academic research groups running discovery-stage programs
- Publicly funded consortia in infectious disease and vaccines
- CDMOs and development partners receiving transferred processes
- Clinical development partners for oncology vaccine programs

## Geography

The group is headquartered in Sweden but its operating business is primarily based in Denmark through ExpreS2ion Biotechnologies ApS at DTU Science Park. Its shareholder base is concentrated in Denmark and Sweden, while research collaborations and development activities extend into broader European and international networks.

- **Sweden** (50%) — Holding company domicile and listing market
- **Denmark** (40%) — Primary operating base and main expense location
- **Other Europe** (10%) — Collaborations, partners and research network

- Holding company listed in Sweden on Nasdaq First North Growth Market
- Operating subsidiary primarily based in Denmark
- Research collaborations span Europe and global vaccine programs
- Currency exposure is mainly SEK versus DKK and EUR
- International development can add USD and GBP exposure

## Strategy

ExpreS2ion’s strategy is to advance ES2B-C001 through early clinical development while preserving ownership of its core oncology asset. At the same time, it uses external collaborations, contract research and platform licensing to demonstrate the versatility of ExpreS2 and share development risk.

- **Advance ES2B-C001 in clinical development** (short-term) — The lead oncology asset is the main proprietary value driver and a key source of future partnering optionality
- **Leverage external collaborations for infectious disease programs** (medium-term) — Partnered programs extend the platform into global health areas while reducing internal capital needs
- **Grow contract research and platform licensing** (medium-term) — Fee-based work and licensing help monetize the platform beyond a single drug asset
- **Expand and protect intellectual property** (long-term) — Patents and know-how support differentiation and future partnering leverage

- Advance ES2B-C001 through Phase I clinical milestones
- Use partnerships to share cost and development risk
- Monetize the ExpreS2 platform through services and licensing
- Build IP around expression and glycosylation technologies
- Maintain a dual model of proprietary assets and external programs

## Risks

The company is exposed to clinical development risk, financing risk and the possibility that early-stage programs do not generate sufficient data to progress. As a biotech platform company, it also faces patent, regulatory, currency and partner-execution risks, with external funding and collaboration central to the business model.

- **Going concern and financing dependence** [critical] — Clinical-stage development requires continued external funding before product revenue can support operations
- **Clinical development failure** [high] — ES2B-C001 and partnered vaccine programs are early-stage and may not produce positive data
- **Patent and technology protection** [high] — The platform’s value depends on proprietary expression methods and related IP
- **Currency risk** [medium] — Operating costs are mainly in DKK/EUR while reporting is in SEK, with potential USD/GBP exposure as development expands
- **Geopolitical and funding volatility** [medium] — International collaboration and investor sentiment can be affected by macro and geopolitical uncertainty

- Clinical programs may fail to show efficacy or tolerability
- External financing is needed to fund development
- Patent protection and know-how are critical to differentiation
- Partner and consortium execution affects milestone delivery
- SEK, DKK, EUR and future USD/GBP exposure can move costs

## Accounting

The most important accounting issue is the treatment of a clinical-stage business with limited recurring revenue and significant judgment around going concern assessment. Investors should also watch how collaboration income, platform service revenue, and any capitalized development or IP-related costs are recognized, because timing can materially affect reported results.

- **Going concern assessment** — Affects liquidity disclosure, valuation assumptions and investor risk assessment
- **Revenue recognition for collaborations and services** — Can shift revenue between periods
- **Foreign currency translation** — Can create translation and transaction gains or losses
- **Development and IP-related costs** — Affects operating loss and asset base
- **Equity and share count changes** — Impacts per-share metrics and dilution analysis

- Going concern assessment depends on future funding and program progress
- Collaboration and fee-for-service revenue timing can be judgmental
- Development and IP-related costs may affect period comparability
- Foreign currency translation matters because costs are mainly in DKK/EUR
- Share-based and equity-linked items can affect reported expense

---

*Last updated: 2026-08-11T04:04:52.516693+00:00*